SCHEMBL26075154

SCHEMBL26075154

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)cc2OC)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ GAA P10253 1/20 0.49
▸ PDE10A Q9Y233 3/20 0.45
▸ PLA2G2A P14555 1/20 0.43
▸ ACACA Q13085 1/20 0.41
▸ SYK P43405 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ ERN1 O75460 1/20 0.39
▸ GRM5 P41594 1/20 0.39
▸ PPM1A P35813 1/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.39
▸ CYP1A1 P04798 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075179 0.92 KDM4E (0.47) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL26075158 0.90 MEN1 (0.47) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL26075148 0.89 PDE10A (0.43) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL26075130 0.88 HMOX1 (0.43) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL26075168 0.86 PDE10A (0.46) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL23590314 0.86 KDM4E (0.70) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL29997481 0.86 KDM4E (0.70) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL26075988 0.84 PDE10A (0.45) KDM4ESMN1; SMN2ALDH1A1GAAPDE10A
SCHEMBL26075298 0.84 HMOX1 (0.45) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL26075173 0.83 SCN9A (0.42) KDM4ESMN1; SMN2ALDH1A1GAAPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD KDM4E 1396/4885SMN1; SMN2 3677/4885MEN1 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback